RFA-RM-24-008: Limited Competition: Competing Revisions to Support Clinical Trials in Somatic Cell Genome Editing (U19 Clinical Trial Required)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.
National Institutes of Health offered grants to state and local governments and tribes. Applications closed on February 13, 2026.
From the official notice on Grants.gov, last changed November 21, 2024. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeCooperative Agreement
About this NIH notice
- Activity codeU19
- Clinical trialsRequired
- Funded byNINDS
- Median yearly award$5.5 million
- Typical project length5 years
- U19, Research Program Cooperative Agreement. Several related projects under one award, with substantial NIH involvement. Other open U19 notices.
Projects funded under RFA-RM-24-008 were run by National Institute of Neurological Disorders and Stroke (NINDS, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-RM-24-008 in the NIH Guide.
Key dates
| Posted | November 21, 2024 |
|---|---|
| Deadline | February 13, 2026 |
| Archived by Grants.gov | March 21, 2026 |
Who can apply
This opportunity was open to state and local governments and tribes.
- Independent school districts
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (72% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit competitive revision (formerly known as competitive supplement) applications from awardees with active U19 awards funded under RFA-RM-22-015 as part ofthe NIH Somatic Cell Genome Editing program, in order to expand the scope of the original award to allow first in human genome editing clinical trials using the therapeutic clinical candidates developed through the U19 award. RFA-RM-22-015 did not allow a clinical trial, whereas the present NOFO (RFA-RM-24-008) requires a clinical trial.
Funded under RFA-RM-24-008 so far
NIH funded 1 project under RFA-RM-24-008 in fiscal 2026, at 1 institution. The median yearly award was $5.5 million.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Postnatal and Prenatal Therapeutic Base Editing for Metabolic Diseases | Children's Hosp of Philadelphia | 2026 | $5.5 million |
Who has won Trans-NIH Research Support grants before
From fiscal 2021 to 2025, Trans-NIH Research Support (93.310) awarded $5.9 billion across 4,433 grant awards, an average of $1.3 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Duke University | North Carolina | 66 | $219 million |
| The Leland Stanford Junior University | California | 104 | $176 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 82 | $154 million |
| The Johns Hopkins University | Maryland | 95 | $152 million |
| Yale Univ | Connecticut | 85 | $149 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-RM-24-008 still open?
No. It closed on February 13, 2026.
Who can apply for Limited Competition: Competing Revisions to Support Clinical Trials in Somatic Cell Genome Editing (U19 Clinical Trial Required)?
National Institutes of Health accepted applications from state and local governments and tribes. The notice adds further conditions, so read its eligibility section.
What is the deadline for Limited Competition: Competing Revisions to Support Clinical Trials in Somatic Cell Genome Editing (U19 Clinical Trial Required)?
Closed February 13, 2026. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under RFA-RM-24-008?
NIH RePORTER lists 1 project funded under RFA-RM-24-008 in fiscal 2026, at 1 institution.
Who has won Trans-NIH Research Support grants before?
The largest recipients over five fiscal years were Duke University, The Leland Stanford Junior University, University of Pittsburgh - of the Commonwealth System of Higher Education. The program made 4,433 awards worth $5.9 billion in that time.
Similar open grants
- Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)
- Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not Allowed)
- Collaborative Initiative on Fetal Alcohol Spectrum Disorders (CIFASD), Research Program (U19 Clinical Trial Optional)
- National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders (U19 Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)